Department of pharmacy practice, Shivlingeshwar college of pharmacy –pharm D, Almala, latur, Maharastra, India. 413520
Research Article
GSC Biological and Pharmaceutical Sciences, 2022, 19(03), 093–099.
Article DOI: 10.30574/gscbps.2022.19.3.0344
Received on 26 November 2021; revised on 01 June 2022; accepted on 03 June 2022
Mucormycosis (zygomycosis) is a fungal infection (serious but rare) caused by a group of molds called mucoromycetes and it is considered the third most common invasive fungal disease after candidiasis and aspergillosis (1) infection occurs by coming in contact with the fungal spores in the environment. There are several types such as Rhino cerebral (sinus and brain) Mucormycosis, Pulmonary (lung) mucormycosis, Gastrointestinal mucormycosis, Cutaneous (skin) Mucormycosis, Disseminated Mucormycosis. Diagnosis is done on the basis of biopsy, histological examination, CT scan or MRI.
With the help of Early diagnosis, Early administration of active antifungal agents, Reversal of underlying factor Complete removal of all infected tissues, use of various adjunctive therapies we can treat Mucormycosis.
In the era of Covid due to exposure of various immunosuppressant’s Mucormycosis cases are hiked, and due to this there is key role of clinical pharmacologist to maintain drug therapy with accurate drug dosing regimen and correlate the drug therapy with other possible risk factors.
This review aims the detailed clinical information of Mucormycosis and Role of Clinical Pharmacologist in the management of Mucormycosis.
Mucormycosis; Fungal infection; Diagnosis; Treatment; Clinical pharmacologist
Preview Article PDF
Pradip Ramesh Lengare, Vishal Tukaram Shinde and Swapnil Ashok Mundhe. Mucormycosis and role of clinical pharmacologist. GSC Biological and Pharmaceutical Sciences, 2022, 19(3), 093-099. Article DOI: https://doi.org/10.30574/gscbps.2022.19.3.0344